TB Research

Rifampicin-Induced Thrombocytopenia: A Case Report and Short Review of the Literature

Epameinondas Koumpis, Konstantina Papathanasiou, Ioannis Papakonstantinou, Iliana Tassi, Anastasia Serpanou, Eleni Kapsali, Eleftheria Hatzimichael

European Medical Journal · 2021-04

Abstract

Thrombocytopenia may be associated with a variety of conditions and risks depending on its severity, ranging from mild epistaxis to life-threating bleeding. Many drugs or herbal remedies can cause thrombocytopenia by either inhibiting platelet production and/or enhancing their destruction from the peripheral blood mediated via an immunological mechanism implicating drug-dependent antibodies. The latter entity is called drug-induced immune thrombocytopenia: a life-threatening, under-recognised condition, which is often a diagnostic challenge. Rifampicin is a widely used, well-tolerated, and effective bactericidal drug. Adverse events, except for gastrointestinal effects, headache, skin rash, and pruritus, are uncommon. The authors herein report on a patient with isolated thrombocytopenia with a recent medical history of brucellosis on rifampicin and doxycycline. Thrombocytopenia was proved to be rifampicin-induced. Also presented is a short review of the literature on this rare subject, which should be of great importance to clinicians.

MeSH terms

  • Medicine
  • Rifampicin
  • Rash
  • Doxycycline
  • Drug
  • Brucellosis
  • Adverse effect
  • Intensive care medicine
  • Medical history
  • Immune thrombocytopenia
  • Drug reaction
  • Platelet
  • Antibiotics
  • Dermatology
  • Immunology